Email Updates

You are here

Home

3 MAY 2019 VOLUME 20 ISSUE 17

Media Coverage

  • US to Continue Funding HIV Treatment in SA

    Intensive remedial efforts by the Department of Health to keep people on HIV treatment have led to the US reversing plans to cut the President’s Emergency Plan for AIDS Relief’s (PEPFAR) funding.

    May 3, 2019
    Treatment
    IOL

  • HIV Proteins’ ‘Social Networks’ Reveal Why Some Patients Control Infection Better Than Others

    In 1994, physician-researcher Bruce Walker was sure he’d stumbled upon the impossible. Despite being HIV positive, the patient in his office was healthy—and had been for at least a decade, all without the help of drugs. But in a year when AIDS would kill 35,000 people in the United States alone, all Walker’s patient wanted to know was when he would die, too.

    May 2, 2019
    General
    PBS

  • Counties Challenged to Allocate More Funds to HIV-AIDS Programs

    A report has shown how allocation of funds to tackle HIV/AIDS in counties is still low, with experts warning that the situation is hindering the achievement of universal healthcare.

    May 2, 2019
    General
    Standard Digital

  • End to AIDS in Sight as Huge Study Finds Drugs Stop HIV Transmission

    An end to the AIDS epidemic could be in sight after a landmark study found men whose HIV infection was fully suppressed by antiretroviral drugs had no chance of infecting their partner.

    May 2, 2019
    Treatment
    The Guardian

  • HIV Vaccine Trial Gathers Momentum

    An African-led first HIV vaccine trial has given hope to millions of people who will only need a few shots to be immunised against the virus. The clinical trial, running from 2018 to 2022 and dubbed PrEVacc, is being conducted in four African countries that include Zimbabwe as Africa takes the lead in the fight against the pandemic. The trial will be one of the highlights at the upcoming 10th conference on HIV science in Mexico.

    April 30, 2019
    HIV Vaccine, PrEP
    Zimbabwe Daily

  • ACT UP Activists Demand Pharma Giant Gilead Stop Blocking Access To HIV Prevention Drug

    Activists from the group ACT UP Dublin gathered outside the Four Courts this morning in protest at the pharmaceutical giant Gilead blocking access to its anti-HIV medication, Truvada. The group demands that Gilead end its efforts to extend its expired patent and significantly drop the price where the patent is still in effect.

    April 30, 2019
    PrEP
    GCN

  • PrEP vs. Privacy

    Although Salvador is 23 years old and lives halfway across the country, his parents back home in the Carolinas always know when he visits his doctor. He doesn’t even need to tell them: Their health insurance provider, which also covers his health care, does that for him. After each medical appointment, an explanation of benefits arrives at his parents’ place detailing every billable procedure, test, and prescription he received during the visit. So, whether Salvador likes it or not, his parents always have a sense of the state of his health.

    April 29, 2019
    PrEP
    Slate

  • Do Feminizing Hormones Impact Efficacy of PrEP Drugs?

    The World Health Organization (WHO) estimates that transgender women are 49 times more likely to be affected by HIV than other populations. Because transgender women are particularly vulnerable to HIV infection, scientists are striving to understand how feminizing hormones impact the efficacy of HIV medication. Unfortunately, this community is also underrepresented when it comes to enrollment in pre-exposure prophylaxis (PrEP) trials.

    April 29, 2019
    Hormonal Contraceptives and HIV, PrEP
    Contagion Live

  • ViiV Applies for Approval of First Long-Acting Injectable HIV Regimen

    Long-acting injectable antiretroviral (ARV) treatment will likely finally become a reality for people living with HIV by the end of the year. ViiV Healthcare has applied to the Food and Drug Administration (FDA) for approval of a long-acting injectable formulation of Janssen’s rilpivirine (currently sold in daily oral pill form as Edurant) and ViiV’s cabotegravir, which is dosed every four weeks through an intramuscular injection (into the muscle, as opposed to under the skin) that requires a clinic visit.

    April 29, 2019
    Treatment
    POZ

  • Plan to End HIV Epidemic in US Must Contend With Uneven State Health Care Systems

    Over the past few months, there's been national buzz around the Department of Health and Human Services plan to end the HIV epidemic in the U.S. by 2030. Federal officials have presented their preliminary strategies at several national conferences and meetings, including the March 2019 National HIV Prevention Conference in Atlanta.

    April 24, 2019
    General
    The BodyPro

  • Senators Push HHS to Take Legal Action Against Gilead Over a Patent for an HIV Drug

    Several US senators have asked the Health and Human Services Department to explain what, if any, steps are being taken to ensure that patents held by the federal government on an HIV prevention pill are properly licensed. The lawmakers also asked agency officials to demonstrate how they take into account whether medicines are affordable when considering licensing patents.

    April 24, 2019
    PrEP
    STAT

Published Research

Announcements